Psyllium: Allergy, Choking and Drug Timing

Table of Contents

1. In Short
2. Choking and Oesophageal Blockage
3. Bowel Blockage and Bezoars
4. Who the Research Raises Concerns For
5. Occupational Allergy: Nurses and Factory Workers
6. Allergy From Swallowing It
7. Medicines Whose Absorption May Be Delayed
8. Pregnancy, Breastfeeding and Children
9. Common Side Effects in Trials
10. Key Research Papers
11. Connections

In Short

• Choking: US regulations record oesophageal obstruction and asphyxiation linked to psyllium and similar swelling gums taken without adequate fluid; dry-form products must carry a “Choking” warning (21 CFR 201.319).
• Bowel blockage: psyllium is among the medicines reported to form “pharmacobezoars”, usually in people with slow gut movement, dehydration or narrowed anatomy.
• Allergy: case reports describe anaphylaxis in nurses previously sensitised by handling the powder, and occupational asthma in a psyllium factory worker. The EMA says ispaghula “contains potent allergens”.
• Medicines: the EMA lists delayed absorption of minerals, vitamin B12, cardiac glycosides, coumarin anticoagulants, carbamazepine and lithium, with possible dose adjustments for thyroid hormones and diabetes treatment.
• Common effects: flatulence and bloating.

Choking and Oesophageal Blockage

The US Code of Federal Regulations contains a specific rule for over-the-counter medicines whose active ingredient is a water-soluble gum or mucilloid — a list that names plantago seed (psyllium) alongside guar gum, glucomannan, methylcellulose, karaya, carrageenan and others (21 CFR 201.319). Its findings, stated in the regulation, are:

• Reports in the medical literature and FDA data indicate that “esophageal obstruction and asphyxiation have been associated with the ingestion” of these substances.
• These are “significant health risks when these products are taken without adequate fluid or when they are used by individuals with esophageal narrowing or dysfunction, or with difficulty in swallowing”.
• Products sold in dry or incompletely hydrated form — capsules, granules, powders, tablets, wafers — must carry a warning under the heading “Choking” stating that taking the product without adequate fluid may cause it to swell and block the throat or oesophagus, and that chest pain, vomiting, or difficulty swallowing or breathing after taking it calls for immediate medical attention.
• Granular psyllium laxatives are “not generally recognized as safe and effective” as over-the-counter products, because the warnings were found inadequate for that form; they need an approved new-drug application.

Foods are covered too. A psyllium food carrying the FDA heart-disease claim, if it contains dry or incompletely hydrated husk, must carry a notice that it is to be eaten with adequate fluid, that eating it without enough liquid may cause choking, and that people with swallowing difficulty are not to eat it (21 CFR 101.17(f)).

The European monograph says the same thing in its own words: when taken with inadequate fluid, bulk-forming agents “can cause obstruction of the throat and oesophagus with choking and intestinal obstruction”, and lists symptoms of chest pain, vomiting, and difficulty swallowing or breathing. It gives “30 ml of water per 1 g” as an example of sufficient liquid (EMA monograph, PDF).

Bowel Blockage and Bezoars

A bezoar is a solid mass that forms in the stomach or intestine. A 1995 review in Digestive Diseases described “pharmacobezoars” — bezoars made of medicines — as an evolving entity, and listed psyllium preparations among the medicines reported to cause them, along with guar gum, aluminium hydroxide gel, sucralfate, cholestyramine, enteric-coated aspirin and some enteral feeds.

The review's key observations were that pharmacobezoars, like bezoars of any kind, most often occur against a background of altered gut motility or anatomy; that bowel underactivity, dehydration, and the use of anticholinergic drugs and opioids contribute; and that the “hygroscopic” (water-attracting) properties of psyllium and guar gum appear to explain their tendency to form masses. These are case-level findings rather than a measured rate, and the EMA lists the frequency of obstruction and faecal impaction as “not known”.

The EMA monograph draws the same links. It describes use alongside medicines that slow the gut (giving opioids as the example) as something done only under medical supervision, notes that treating debilitated and elderly patients requires medical supervision, and states that faecal impaction with abdominal pain, nausea and vomiting can be signs of an existing or impending blockage (ileus).

Who the Research Raises Concerns For

Pulling the regulatory texts and case literature together, the groups in whom these hazards are concentrated are:

• People with swallowing difficulty or a narrowed oesophagus — named in both the US warning and the EMA contraindications. Conditions such as achalasia involve exactly this kind of oesophageal dysfunction.
• People with narrowing anywhere in the gut, or a known or suspected blockage — listed by the EMA as contraindications.
• People with slow gut movement — including those taking opioids or anticholinergic drugs, and conditions such as gastroparesis, which the bezoar review links to mass formation.
• Frail and elderly patients, and people who are dehydrated — named in the EMA monograph and the bezoar review.
• People with a sudden change in bowel habit lasting more than two weeks, or unexplained rectal bleeding — listed by the EMA as contraindications, because these call for diagnosis rather than a laxative.
• People with existing psyllium sensitivity, particularly after occupational exposure (below).

Occupational Allergy: Nurses and Factory Workers

Psyllium allergy is primarily an occupational story. People who scoop, mix or dispense the powder day after day breathe it in, and inhaled plant protein is an efficient way to become sensitised.

Two nurses (1990)

A Toronto report, titled simply “Psyllium anaphylaxis”, states that allergic reactions from handling psyllium had been reported since 1970, and that health professionals and laxative-manufacturing workers are at greatest risk. It described two nurses:

• A 39-year-old dialysis nurse with a 3-year history of nose and eye symptoms on exposure to psyllium took an over-the-counter psyllium laxative for constipation and developed flushing, a racing heart, hives, swelling of the face and throat (including the larynx) and light-headedness. Skin and blood tests for psyllium allergy were strongly positive.
• A 42-year-old nurse with asthma, who had nose and eye symptoms while dispensing psyllium, took a prescribed psyllium product by mouth and developed flushing, a racing heart, hives and swelling. With a later dose she also had severe wheezing, light-headedness and loss of consciousness.

The authors concluded that ingestion by sensitised people — “such as from a routine postoperative and postpartum order” — is potentially dangerous.

A factory worker (1995)

A Spanish primary-care series on work-related asthma included a 19-year-old man working in psyllium manufacture who had a month-long morning cough. Peak-flow monitoring showed a slow 25% fall in maximum expiratory flow, allergy testing showed sensitivity to psyllium, and he became symptom-free once separated from the exposure.

What the regulator says

The EMA monograph states that “ispaghula contains potent allergens”, that exposure can occur by mouth, by skin contact and, for powders, by inhalation, and that people with continued occupational contact with the powder, “i.e. healthcare workers, caregivers”, can become sensitised — more often if they are atopic (prone to allergies). Reported reactions include rhinitis, conjunctivitis, bronchospasm and, in some cases, anaphylaxis. For powder products the monograph's directions include minimising inhalation of the powder while preparing it (EMA). The site's Asthma page covers occupational asthma more broadly.

Allergy From Swallowing It

Sensitisation does not require occupational inhalation. A 1994 report in the Annals of Allergy described a 40-year-old woman who, two years after starting a regular psyllium laxative, developed an itchy rash with hives across her whole body including palms, soles and the inside of the mouth, along with chest and throat tightness and lip swelling. The symptoms resolved when she stopped psyllium and returned immediately on a supervised challenge. Her psyllium-specific IgE was positive.

The author's review of the literature concluded that the allergens in psyllium “appear to be protein in nature and derived from the inner seed endospore and embryo rather than from the husk itself” — which suggests that how thoroughly a husk product is separated from the seed may matter, though this was not tested directly. The same report notes that this patient was sensitised and challenged by mouth.

A 1999 French review of “new food allergies” listed psyllium among emerging food allergens, alongside spices, sesame, sunflower seed and exotic fruits such as kiwi. The site's Food Allergy and Anaphylaxis pages describe how these reactions are diagnosed and treated.

Medicines Whose Absorption May Be Delayed

The EMA monograph's interaction section is short and specific (EMA monograph, PDF):

• Delayed absorption: “Enteral absorption of concomitantly administered medicines such as minerals, vitamins (B12), cardiac glycosides, coumarin derivatives, carbamazepine and lithium may be delayed.” In plain terms: mineral supplements, vitamin B12, heart medicines of the digoxin type, warfarin-type anticoagulants, the anti-seizure drug carbamazepine, and lithium.
• Spacing: for that reason the monograph separates psyllium from other medicines by half an hour to an hour, and describes taking it during the day rather than immediately before bed.
• Thyroid hormones: use alongside thyroid hormones “requires medical supervision because the dose of the thyroid hormones may have to be adjusted”. See Hypothyroidism.
• Diabetes: people with diabetes take it under medical supervision because anti-diabetic therapy may need adjusting.
• Gut-slowing medicines: use with medicines that inhibit gut movement, such as opioids, only under medical supervision, to reduce the risk of blockage.

The monograph frames the interaction as delayed absorption; it does not give figures for how large the effect is for each drug, and none of the PubMed records used for this page measured it. Questions about timing a particular prescription belong with the prescriber or a pharmacist.

Pregnancy, Breastfeeding and Children

• Pregnancy: the EMA reports a limited amount of data (fewer than 300 pregnancy outcomes) and says animal studies are insufficient on reproductive toxicity. Its text states that use “may be considered during pregnancy and lactation, if necessary and if change of nutrition is not successful”, and that bulk laxatives come before other purgatives.
• Breastfeeding: the US National Library of Medicine's LactMed database states that few data exist, but because psyllium is not absorbed from the gut it cannot enter breast milk, and it describes psyllium as acceptable during breastfeeding.
• Children: the EMA gives a lower dose range for ages 6–12 and does not recommend use under 6 years for constipation (or under 12 for the fibre-supplement indication). A 2021 paediatric review found that psyllium's supporting studies in constipation are in adults.

Common Side Effects in Trials

• Flatulence: significantly more common with fibre than control in the 2022 meta-analysis of 16 constipation trials. The EMA notes that it generally disappears as treatment continues.
• Compared with fruit: in a 2021 US trial of kiwifruit, prunes and psyllium for constipation, adverse events were most common with psyllium.
• Across over-the-counter laxatives: diarrhoea, nausea, bloating and abdominal pain were common, and no serious adverse events were reported in the trials reviewed in 2021.
• In a large fibre trial: a 2023 trial's plain-language summary noted that bloating and flatulence are major concerns with high fibre intake.
• In appetite trials: most adverse events were mild gut symptoms, similar to placebo.

The contrast with the rare but serious hazards above is the overall shape of psyllium's safety profile: frequent minor gut effects, and uncommon serious events concentrated in identifiable situations — too little fluid, a narrowed or slow gut, prior sensitisation, or a medicine with a narrow dose margin taken at the same time.

Key Research Papers

1. Sussman GL, Dorian W. Psyllium anaphylaxis. Allergy proceedings : the official journal of regional and state allergy societies. 1990;11(5):241-2. — two nurses sensitised by handling psyllium developed anaphylaxis after swallowing it. PubMed PMID: 2258044
2. Freeman GL. Psyllium hypersensitivity. Annals of allergy. 1994;73(6):490-2. — whole-body hives and throat tightness after two years of laxative use; positive challenge and IgE. PubMed PMID: 7998662
3. Ferrer Marín-Blázquez M, Gázquez Abad I, Herrera Puente P, et al. [Occupational asthma]. Atencion primaria. 1995;15(1):33-5. — occupational asthma in a psyllium-manufacturing worker (Spanish). PubMed PMID: 7880953
4. Dutau G, Rittié JL, Rancé F, et al. [New food allergies]. Presse medicale (Paris, France : 1983). 1999;28(28):1553-9. — psyllium listed among emerging food allergens (French). PubMed PMID: 10526567
5. Stack PE, Thomas E. Pharmacobezoar: an evolving new entity. Digestive diseases (Basel, Switzerland). 1995;13(6):356-64. — psyllium preparations among causes of pharmacobezoars; risk factors. PubMed PMID: 8590522
6. Psyllium. Drugs and Lactation Database (LactMed®). Bethesda (MD): National Institute of Child Health and Human Development; 2006–. — not absorbed; cannot enter breast milk; acceptable in breastfeeding. PubMed PMID: 30000405
7. McRorie JW Jr, McKeown NM. Understanding the Physics of Functional Fibers in the Gastrointestinal Tract: An Evidence-Based Approach to Resolving Enduring Misconceptions about Insoluble and Soluble Fiber. Journal of the Academy of Nutrition and Dietetics. 2017;117(2):251-264. — why the gel holds water through the colon. PubMed PMID: 27863994
8. van der Schoot A, Drysdale C, Whelan K, et al. The Effect of Fiber Supplementation on Chronic Constipation in Adults: An Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials. The American journal of clinical nutrition. 2022;116(4):953-969. — flatulence more common with fibre in 16 constipation trials. PubMed PMID: 35816465
9. Chey SW, Chey WD, Jackson K, et al. Exploratory Comparative Effectiveness Trial of Green Kiwifruit, Psyllium, or Prunes in US Patients With Chronic Constipation. The American journal of gastroenterology. 2021;116(6):1304-1312. — adverse events most common with psyllium versus kiwifruit and prunes. PubMed PMID: 34074830
10. Rao SSC, Brenner DM. Efficacy and Safety of Over-the-Counter Therapies for Chronic Constipation: An Updated Systematic Review. The American journal of gastroenterology. 2021;116(6):1156-1181. — common gut adverse events; no serious events across over-the-counter laxatives. PubMed PMID: 33767108
11. Lai H, Li Y, He Y, et al. Effects of dietary fibers or probiotics on functional constipation symptoms and roles of gut microbiota: a double-blinded randomized placebo trial. Gut microbes. 2023;15(1):2197837. — bloating and flatulence noted as concerns with high fibre intake. PubMed PMID: 37078654
12. Brum JM, Gibb RD, Peters JC, et al. Satiety effects of psyllium in healthy volunteers. Appetite. 2016;105:27-36. — mild gut adverse events similar to placebo in appetite trials. PubMed PMID: 27166077
13. Santucci NR, Chogle A, Leiby A, et al. Non-pharmacologic approach to pediatric constipation. Complementary therapies in medicine. 2021;59:102711. — psyllium's constipation evidence is from adults. PubMed PMID: 33737146

PubMed Topic Searches

1. Psyllium hypersensitivity and anaphylaxis
2. Psyllium occupational asthma in healthcare workers
3. Psyllium oesophageal obstruction and bezoar
4. Psyllium and drug absorption

Back to Table of Contents

Connections

• Psyllium (Plantago ovata) — the main page
• Psyllium: Benefits Deep Dive — the evidence hub
• Cholesterol and Heart Health — the health claim that carries the choking notice
• Blood Sugar and Diabetes — why diabetes medicines are mentioned
• IBS, Constipation and Diarrhoea — the main uses
• Digestive and Gut Herbs — the category
• Plantain: Its Psyllium Relatives — the leaf relative and medicine timing
• Anaphylaxis — the severe allergic reaction
• Food Allergy — allergy from swallowed foods
• Asthma — including occupational asthma
• Achalasia — an oesophageal swallowing disorder
• Gastroparesis — slow stomach emptying
• Hypothyroidism — thyroid hormone dosing
• Constipation — the symptom

Back to Table of Contents